Research Article

In Vitro Antibacterial and Time-Kill Evaluation of the Erythrina caffra Thunb. Extract against Bacteria Associated with Diarrhoea

Olufunmiso Olusola Olajuyigbe and Anthony Jide Afolayan

Phytomedicine Research Centre, Department of Botany, University of Fort Hare, Alice 5700, South Africa

Correspondence should be addressed to Anthony Jide Afolayan, aafolayan@ufh.ac.za

Received 23 August 2012; Accepted 4 October 2012

Academic Editors: A. Corsetti and G. A. Rocha

Copyright © 2012 O. O. Olajuyigbe and A. J. Afolayan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The antibacterial activities of stem bark ethanolic extract of Erythrina caffra Thunb. against bacteria in diarrhoea was determined in vitro by the agar diffusion and dilution, macrobroth dilution, and time-kill assay methods. The result showed that the extract produced inhibition zones ranging between 15 ± 1.0 mm and 23 ± 1.0 mm, and the bacteria were susceptible at concentrations ranging between ≤100 and ≤1000 μg/mL. While the MICs of the extract ranged between 39.1 and 625 μg/mL, and the MBCs ranged between 78.1 and 625 μg/mL, the MICs of Micrococcus luteus, Proteus vulgaris CSIR 0030, Enterococcus faecalis KZN, and Staphylococcus aureus OK3 were less than 100 μg/mL, and the mechanisms of antibiosis indicated that the crude ethanolic extract was highly bactericidal against the entire test bacteria isolates. In the time-kill assay, the average log reduction of the viable cell count ranged between 0.916log10 and 1.851log10 cfu/mL on incubating the bacteria for 4 h at the MICs, while the reduction ranged between 0.183log10 and 1.105log10 cfu/mL after 8 h of incubation. Incubating the bacteria for 4 h at 2 × MICs resulted in the reduction of the viable cell count to between –0.264log10 and 0.961log10 cfu/mL, while the average log reduction ranged between –3.968log10 and –0.423log10 cfu/mL after 8 h of incubation with Micrococcus luteus, Proteus vulgaris CSIR 0030, and Staphylococcus aureus OK3 being the most highly affected bacteria. The result showed that the extract exhibited broader-spectrum antibacterial activity and justifies the use of Erythrina caffra in the folkloric medicine for treating gastrointestinal infections in South Africa.

1. Introduction

In medical parlance, antibiotic resistance defines the epidemiology and pharmacological therapy of infectious diseases while the increasing incidence of resistance to antimicrobials is a growing concern of the medical arena [1, 2]. To avert the menace of the pathogens resistant to antibacterial agents, attention has been focused on discovering new antimicrobial compounds of microbial and plant origins [3, 4]. Natural products, especially from plants, have been considered interesting alternatives for treatment [5] because they are rich in a numerous variety of secondary metabolites with antimicrobial properties [6]. These secondary metabolites which are pharmacologically bioactive compounds include alkaloids, flavanoids, tannins, anthraquinones, and phenolic compounds [7, 8].

Diarrhoea, an important clinical problem [9] and a leading cause of morbidity and mortality in developed and developing countries [10, 11], is an intestinal infection responsible for death in the elderly in industrialized countries [12] and the deaths of 3-4 million infants and young children each year worldwide [13]. It accounted for 1.78 million deaths in low- and middle-income countries [14]. Being a divergence from the established rhythm of bowel movement, it is characterized by an increase in frequency and fluidity of stools resulting from dysentery, food poisoning, bacterial and viral infections, allergy to certain foods, and changes in climatic conditions. Epidemiologically, rotavirus is the most common cause of mortality in children [15]. Important bacterial pathogens mostly implicated in diarrhoea are diarrheagenic Escherichia coli, Salmonella typhi, Bacillus cereus, Campylobacter jejuni, Aeromonas hydrophila, Shigella...
spp., *Yersinia* spp. and *Vibrio cholera*, and the main causative parasites in contaminated domestic water supplies included *Giardia intestinalis* and *Cryptosporidium parvum* [16]. During oral rehydration, breast and complementary feeding in children is essential in reducing the discomfort and inconvenience of frequent bowel movements [17], and use of medicines derived from plants is sought after by the indigenous populace from traditional healers because they are cheaper than modern medicine [18]. Based on this concept, several studies have evaluated the effectiveness of some traditional medicines in treating diarrhoea on all the different continents [19], while a programme involving the use of herbal medicines in treating diarrhoea on all the different studies have evaluated the effectiveness of some traditional medicines for diarrhoea control in the developing countries was introduced by WHO [20].

*Erythrina* is a genus of flowering plants in the pea family, Fabaceae, consisting of nine different species including the *Erythrina lysistemon* and *Erythrina caffra* being common in the Southern Africa. They are often cultivated as ornamental, street, and park trees in drier areas to provide shade and improve soil quality by fixing nitrogen for other tree crops. Traditionally, the genus has been prominently used for female infertility, gonorrhrea [21], stomach pains, and microbial infections [22]. *Erythrina caffra* Thunb., the coast coral tree, native to Southen Africa, has warm red- to scarlet-coloured flowers which appear from the cold winter months up to spring. It is found in the coastal regions of the Eastern Cape of South Africa. In traditional medicine, its bark is used to treat sores, tuberculosis, respiratory infections, wounds, abscesses, arthritis and toothache. The infusions of the leaves are used as eardrops for earache. The decoctions of the roots are used for sprains [23, 24]. Despite its use suggesting antibacterial, anti-inflammatory, antitumor, anti-blood-clotting, and analgesic effects, there is a dearth of scientific reports on *E. caffra* as a plant of medicinal importance. As a result, this study was aimed at investigating the ethnotherapeutic efficacies of *E. caffra* against bacteria associated with diarrhoea infection to justify its use in traditional medicine in the Eastern Cape of South Africa.

### 2. Materials and Methods

#### 2.1. Collection of Plant Material

The bark materials of *E. caffra* were collected in September, 2010, from the plant growing within the University of Fort Hare campus in Alice, South Africa. The plant was authenticated in the Department of Botany, and a voucher specimen was prepared and deposited in the Griffin Herbarium of the University.

#### 2.2. Extract Preparation

The bark sample was air-dried at room temperature, pulverized with a milling machine, and extracted in accordance with the description of Basri and Fan [25]. Briefly, about 100 g of the pulverized sample was extracted with 500 mL of ethanol for 72 h with shaking (Stuart Scientific Orbital Shaker, Staffordshire, UK). The extract was filtered through Whatman no. 1 filter paper and concentrated under reduced pressure at 40°C using a rotary evaporator (Laborota 4000-efficient, Heidolph city Germany). The crude extract collected was allowed to dry at room temperature to a constant weight of 3.5 g. The extract was redissolved in dimethylsulfoxide (DMSO) to the required concentrations for bioassay analysis. The reconstituted extract solution was sterilized by filtering through 0.45 μm membrane filter and tested for sterility after membrane filtration by introducing 2 mL of the extract in 10 mL of sterile nutrient broth before being incubated at 37°C for 24 h. A sterile extract was indicated by the absence of turbidity in the broth after the incubation period.

#### 2.3. Test Organisms and Inocula Preparation

The bacteria used in this study included *Proteus vulgaris* CSIR 0030, *Proteus vulgaris* KZN, *Shigella flexneri* KZN, *Micrococcus luteus*, *Enterococcus faecalis* KZN, *Staphylococcus aureus* OK3, *Shigella sonnerati* (ATCC 29930), *Escherichia coli* (ATCC 25922), *Bacillus pumilus* (ATCC 14884), *Enterococcus faecalis* (ATCC 29212), *Pseudomonas aeruginosa* (ATCC 19582), and *Staphylococcus aureus* (ATCC 6538). The inocula of the test bacteria were prepared using the colony suspension method [26]. Colonies picked from 24 h old cultures grown on nutrient agar were used to make suspensions of the test organisms in saline solution to give an optical density of approximately 0.1 at 600 nm. The suspension was then diluted 1:100 by transferring 0.1 mL of the bacterial suspension to 9.9 mL of sterile nutrient broth before being used.

#### 2.4. Antimicrobial Assay by Agar Diffusion (Inhibition Zones) and Agar Dilution Methods

For the initial determination of the antibacterial activity of the crude ethanol extract of *E. caffra*, the susceptibility screening of the test bacteria to the extract and ciprofloxacin, used as control, was determined by using the modified Kirby-Bauer diffusion technique [27] involving swabbing Mueller-Hinton agar (MHA) (Oxoid Ltd, Basingstoke, Hampshire, UK) plates with the resultant saline suspension of each adjusted bacterial strain. Wells were then bored into the agar medium using a heat-sterilized 6 mm cork borer. The wells were filled with 100 μL of different concentrations of the extract (625 μg/mL, 1250 μg/mL, 2500 μg/mL, 5000 μg/mL, 10000 μg/mL, and 20000 μg/mL) taking care not to allow spillage of the solutions onto the surface of the agar. The culture plates were allowed to stand on the laboratory bench for 1 h to allow proper diffusion of these solutions before being incubated at 37°C for 24 h. Wells in blank Mueller Hinton agar containing 10% DMSO representing the final concentration of the DMSO in the test plates without the extract served as negative control. The determinations were done in duplicates. After 24 h of incubation, the plates were examined if there is any inhibition zone. The diameters of the inhibition zones produced by each of the concentrations of the solutions were measured in millimeters [28] and interpreted using the CLSI zone diameter interpretative standards [29].

To determine the antibacterial activity of the extract by the agar dilution method described by Afolayan and Meyer [30], different concentrations of the extract ranging between 100 and 10000 μg/mL were prepared in molten Mueller Hinton agar maintained in a water bath at 50°C and used for the agar dilution assay. One hundred microlitres (100 μL) of the standardized bacterial cultures was aseptically dispensed and spread evenly on the agar plates. Two Mueller Hinton
agar plates containing 5% ethanol representing the final ethanol concentration in the test plates without the extract served as negative controls. Another two blank plates containing only Mueller Hinton agar served as negative controls. Plates were incubated aerobically at 37°C for 24 h. Each test was done in triplicate, and any test agar plate lacking visible growth was considered the minimum inhibitory concentration of the extract.

2.5. Macrobeth Dilution for Determining Minimum Inhibitory Concentration (MIC). Minimum inhibitory concentration (MIC) defined as the lowest concentration which resulted in maintenance or reduction of inoculums’ viability was determined by serial tube dilution technique for the bacterial isolates. Different concentrations (19.5–10000) µg/mL of the crude extract and (0.0195–10) µg/mL of ciprofloxacin were differently prepared by serial dilutions in the Mueller Hinton broth medium. Each tube was then inoculated with 100 µL of each of the adjusted bacterial strains. Two blank Mueller Hinton broth tubes, with and without bacterial inoculation, were used as the growth and sterility controls. The bacteria-containing tubes were incubated aerobically at 37°C for 24 h. After the incubation period, the tubes were observed for MICs by checking the concentration of the first tube in the series (ascending extract and antibiotic concentrations) that showed no visible trace of growth. The first tube in the series with no visible growth after the incubation period was taken as the MIC.

2.6. Determination of Minimum Bactericidal Concentrations (MBC). The MBC was determined by sampling all the macroscopically clear tubes and the first turbid tube in the series. Before being sampled, the tubes were gently mixed by flushing them with a sterile pipette, and a 100 µL aliquot was removed. Each aliquot was placed on a single antibiotic-free nutrient agar plate in a single streak down the center of the plate in accordance with the method of Shanholtzer et al., [31]. The samples were allowed to be absorbed into the agar until the agar surface appeared dry (after 30 min). The aliquot was then spread over the plate by making a lawn of the bacterial culture with a sterile cotton swab. In many studies on microbial susceptibility, this subculturing method has been found satisfactory in eliminating the problem of antimicrobial agent carryover from the 100 µL subcultured volume [32–35]. The growth and sterility controls were sampled in the same manner. The MBC-determining lawned plates were incubated for 24 h at 37°C. After the incubation periods, the lowest concentrations of the extract that did not produce any bacterial growth on the solid medium were regarded as the MBC values for this crude extract [36]. This observation was matched with the MIC test tube that did not show evidence of growth after 48 h of incubation.

2.7. Determination of Mechanisms of Antibiosis (Bactericidal or Bacteriostatic). The mechanism of antibiosis of the extracts was calculated using the ratio of MBC/MIC or MIC\textsubscript{index} as described by Shanmughapriya et al. [37] to elucidate whether the observed antibacterial effects were bactericidal or bacteriostatic. When the ratio of MBC/MIC was ≤2.0, the extract was considered bactericidal or otherwise bacteriostatic. If the ratio is ≥16.0, the extract was considered ineffective.

2.8. Determination of Rate of Kill. Assays for the rate of killing bacteria by the crude ethanolic extract were carried out using a modified plating technique of G. M Eliopoulos and C. T. Eliopoulos [38] and Eliopoulos and Moellering [39]. The extract was incorporated into 10 mL Mueller Hinton broth in McCartney bottles at 1/2 MIC, 1 × MIC, and 2 × MIC. Two controls, one Mueller Hinton broth without extract inoculated with test organisms and Mueller Hinton broth incorporated with the extract at the test concentrations without the test organisms, were included. Inoculums density, approximately 10^5 cfu/mL further verified by total viable count, was used to inoculate 10 mL volumes of both in the McCartney bottles and control bottles. The bottles were incubated at 37°C on an orbital shaker at 120 rpm. A 100 µL aliquot was removed from the culture medium at 0, 4, and 8 h for the determination of cfu/mL by the plate count technique [40] by plating out 25 µL of each of the dilutions. The problem of extract carryover was addressed by dilution as described previously by Pankuch et al., [41]. After incubating at 37°C for 24 h, emergent bacterial colonies were counted, cfu/mL calculated, and compared with the count of the culture control without the extract.

3. Results

The antibacterial activity of the stem bark ethanolic extract of E. caffra was evaluated by both agar diffusion and dilution assays against bacteria associated with diarrhoeal infection. The degree of the antibacterial activity was assayed by serial twofold dilution method to determine the minimum inhibitory concentration (MIC) of the extract [42]. The two assay methods showed that the bacteria exhibited varied susceptibility to the extract at the different concentrations used. The zones of inhibition obtained from 2.5 µg/mL of ciprofloxacin ranged between 17 and 38 ± 1.0 mm. At the highest concentration of the extract (20000 µg/mL), Proteus vulgaris CSIR 0030 had the widest zone of inhibition (23 ± 1.0 mm), while Proteus vulgaris KZN and Staphylococcus aureus (ATCC 6538) had the least zone of inhibition (15 ± 1.0 mm). Of these isolates, only Proteus vulgaris CSIR 0030, Shigella sonner (ATCC 29930), Escherichia coli (ATCC 2922), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 19582) had different zones of inhibition from 100 µL of the least concentration (650 µg/mL). The bacteria were not susceptible to 10% DMSO used in the control assay. The agar dilution indicated that the bacteria were susceptible to the extract at concentrations ranging between ≤100 and ≤1000 µg/mL. From the agar dilution assay, Micrococcus luteus, Proteus vulgaris CSIR 0030, Enterococcus faecalis KZN, and Staphylococcus aureus OK3 had MICs less than or equal to 100 µg/mL; Shigella flexneri KZN, Proteus vulgaris KZN, Shigella sonner (ATCC 29930), Bacillus pumilus (ATCC 14884), Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 6538), and Pseudomonas aeruginosa (ATCC 19582) had their MICs less than or equal to
Table 1: Results of agar diffusion assays to determine the antibacterial activity of the crude ethanolic extract of *E. caffra*.

| Tested bacterial isolates | Average zones of inhibition (±1.0 mm) | Ciprofloxacin | Ethanol extract |
|---------------------------|----------------------------------------|---------------|----------------|
|                           |                                        | 2.5 | 650 | 1250 | 2500 | 5000 | 10000 | 20000 | MIC |
| *Micrococcus luteus*      |                                        | 17  | 0   | 0    | 14   | 17   | 19    | ≤100  |
| *Shigella flexneri KZN*   |                                        | 26  | 0   | 0    | 13   | 15   | 15    | ≤500  |
| *Proteus vulgaris KZN*    |                                        | 35  | 0   | 0    | 14   | 15   | 15    | ≤500  |
| *Proteus vulgaris CSIR 0030* |                                    | 31  | 14  | 17   | 18   | 20   | 21    | ≤100  |
| *Enterococcus faecalis KZN* |                                    | 19  | 0   | 0    | 13   | 15   | 16    | ≤100  |
| *Staphylococcus aureus OK1* |                                    | 38  | 0   | 0    | 12   | 14   | 17    | ≤100  |
| *Shigella sonnei* (ATCC 29930) |                                    | 22  | 13  | 14   | 15   | 17   | 18    | ≤500  |
| *Bacillus pumilus* (ATCC 14884)* |                                   | 25  | 0   | 0    | 16   | 18   | 19    | ≤500  |
| *Escherichia coli* (ATCC 25922)* |                                   | 26  | 11  | 12   | 13   | 15   | 17    | ≤1000 |
| *Enterococcus faecalis* (ATCC 29212)* |                                   | 25  | 15  | 15   | 17   | 19   | 21    | ≤500  |
| *Staphylococcus aureus* (ATCC 6538)* |                                   | 34  | 0   | 0    | 11   | 13   | 13    | ≤500  |
| *Pseudomonas aeruginosa* (ATCC 19582)* |                               | 26  | 13  | 13   | 15   | 17   | 18    | ≤500  |

Table 2: Antibacterial activity of the ethanolic extract of *Erythrina caffra* Thunb.

| Tested bacterial isolates | Macrobroth dilution | Ethanol extract |
|---------------------------|---------------------|----------------|
|                           | MIC | MBC | MIC<sub>index</sub> | MIC | MBC | MIC<sub>index</sub> |
| *Micrococcus luteus*      | 0.1563 | 0.3125 | 2 | 39.1 | 78.1 | 2 |
| *Shigella flexneri KZN*   | 0.0390 | 0.0781 | 2 | 156.3 | 312.5 | 2 |
| *Proteus vulgaris KZN*    | 0.3125 | 0.6250 | 2 | 156.3 | 156.3 | 1 |
| *Proteus vulgaris CSIR 0030* | 0.1563 | 0.1563 | 1 | 39.1 | 39.1 | 1 |
| *Enterococcus faecalis KZN* | 0.1563 | 0.6250 | 2 | 78.1 | 78.1 | 1 |
| *Staphylococcus aureus OK1* | 1.2500 | 1.2500 | 1 | 39.1 | 78.1 | 1 |
| *Shigella sonnei* (ATCC 29930) | 0.1563 | 0.1563 | 1 | 312.5 | 312.5 | 1 |
| *Bacillus pumilus* (ATCC 14884) | 0.0391 | 0.0319 | 1 | 156.3 | 156.3 | 1 |
| *Escherichia coli* (ATCC 25922) | 0.0195 | 0.0195 | 1 | 625.0 | 625.0 | 1 |
| *Enterococcus faecalis* (ATCC 29212) | 0.6250 | 2.5000 | 4 | 156.3 | 156.3 | 1 |
| *Staphylococcus aureus* (ATCC 6538) | 0.3125 | 0.6250 | 2 | 312.5 | 312.5 | 1 |
| *Pseudomonas aeruginosa* (ATCC 19582) | 0.0781 | 0.1563 | 1 | 156.3 | 312.5 | 2 |

500 μg/mL, while the susceptibility of *Escherichia coli* (ATCC 25922) indicated a higher MIC value less than or equal to 1000 μg/mL (Table 1).

The macrobroth dilution assay to determine the degree of the antibacterial activity showed that the minimum inhibitory concentrations (MICs) of ciprofloxacin against the bacteria were generally below 1 μg/mL, and the minimum bactericidal concentrations (MBCs) ranged between 0.0319 μg/mL and 2.5 μg/mL with the exception of *Staphylococcus aureus* OK1 having an MIC and MBC values of 1.25 μg/mL. The MICs of the extract against all the bacteria isolates ranged between 39.1 and 625 μg/mL, and the MBCs ranged between 78.1 and 625 μg/mL. While the MICs of *Micrococcus luteus*, *Proteus vulgaris CSIR 0030*, *Enterococcus faecalis* KZN, and *Staphylococcus aureus* OK1 were less than 100 μg/mL, those of *Shigella flexneri KZN*, *Proteus vulgaris KZN*, *Bacillus pumilus* (ATCC 14884), *Enterococcus faecalis* (ATCC 29212), and *Pseudomonas aeruginosa* (ATCC 19582) equal to 156.3 μg/mL; *Shigella sonnei* (ATCC 29930), and *Staphylococcus aureus* (ATCC 6538) had 312.5 μg/mL and *Escherichia coli* (ATCC 25922) had the highest MIC value of 625 μg/mL (Table 2). The determination of the mechanisms of antibiosis indicated that both ciprofloxacin and the crude ethanolic extract were highly bactericidal against the entire test bacteria isolates, even though, the extract was considered not as effective as the antibiotic. While the MBCs of the antibiotic were similar or two- to four-folds higher than the MICs, the MBCs of the extract were similar or twofolds higher than the MICs.

In the time-kill assay, the results presented in terms of the changes in the log<sub>10</sub> cfu/mL of viable colonies indicated that the extract exhibited a significant bactericidal activity.
The bactericidal activity was defined as being equal to 3log₁₀ cfu/mL or greater reduction in the viable colony count relative to the initial inoculum [43]. The results of the time-kill assay are presented in Table 3. After 4 h of incubating the bacteria with the 1 × MICs, the average log reduction in the viable cell count ranged between −0.264log₁₀ and 0.916log₁₀ cfu/mL. After 8 h of incubation with these different concentrations, the average log reduction in the viable cell count ranged between −3.968log₁₀ and 1.105log₁₀ cfu/mL. At the 1 × MICs, the bacteria for 4 h resulted in the reduction of the viable cell count ranging between 0.916log₁₀ and 1.851log₁₀ cfu/mL, while at 8 h, the reduction ranged between 0.183log₁₀ and 1.105log₁₀ cfu/mL. At 2 × MICs, incubating the bacteria for 4 h resulted in the reduction of the viable cell count that ranged between −0.264log₁₀ and 0.961log₁₀ cfu/mL while after 8 h of incubation, the average log reduction in the viable cell count ranged between −3.968log₁₀ and −0.425log₁₀ cfu/mL with Micrococcus luteus, Proteus vulgaris CSIR 0030, and Staphylococcus aureus OK₃ being the most highly affected bacteria of all the isolates.

4. Discussion

Medicinal plants have been unique sources of medicines and constituted the most common human use of biodiversity [44]. The traditional use of medicinal plants, being before the advent of antibiotics and other modern drugs [45] and their use worldwide for thousands of years with more than 80% of the world's population depending on traditional medicines for various diseases [46], implicated the anticipations of scientists that phytochemicals with adequate antibacterial efficacy will be useful for the treatment of bacterial infections [47]. Consequently, many ethnomedical studies are being conducted to determine their safety, efficiency, and discovery of new active principles in the recent times [48] while many medicinal plants and plants' products with antibiotic actions have become a significant source of many potent and powerful drugs [49, 50] as well as the main source of new leads for antimicrobial remedies and pharmaceutical development [51].

In this study, the crude ethanolic extract of E. caffra demonstrated significant inhibitory and bactericidal effects against all the test bacteria isolates. The differences in the values of MICs and MBCs suggested a selective antibacterial activity of the extract, while the varied susceptibility of the different bacteria isolates was extract concentration-dependent. Although Rios and Recó [52] suggested that MICs greater than 1000 μg/mL of crude extracts or 100 μg/mL for isolated compounds should be avoided and proposed that activity would be very interesting in MICs of 100 μg/mL and 10 μg/mL for crude extracts and isolated compounds respectively, Fabry et al. [53] defined active crude extracts as those having MIC values <8000 μg/mL. Hence, since lower MIC and MBC values indicate higher efficacy [54], and phytochemicals are routinely classified as antimicrobials when susceptibility tests had MICs in the range of 100–1000 μg/mL [55], the MICs and MBCs of less than 1000 μg/mL, in this study, were considered to be of good activity. The MICs and MBC values, being less than or equal to 2, indicated the bactericidal attribute of the crude ethanolic extract and suggested that bactericidal effects of the crude extract could be expected on most of the tested organisms [56] in a disease state. Where MIC equals MBC, the bactericidal potential with a broad spectrum and great therapeutic potential of the plant is indicated.

Furthermore, the resultant effect of incubating the bacteria at 2 × MICs was a significantly rapid reduction in the average log of the viable cells counted. This reduction is greater than the rate of kill observed in the bacteria isolates treated with the 1 × MICs. The significant reduction in the cell counts between 4 and 8 h of incubation period acknowledged the fact that the extract was highly bactericidal seeing that the bacterial colonies were almost totally wiped out after incubating for 8 h. On the contrary, there was a net growth of all the test isolates treated with the 1/2 × MICs.
of the extract. While the growth inhibition and efficacy of the crude ethanolic stem bark extract were dose and time dependent to present effective time-kill profiles for the tested bacteria, the results of the antibacterial assays determined by the agar diffusion and dilution methods as well as the macrobroth dilution assay are complementary. These results were further substantiated by the observed rate of kill and the effectiveness of the extract’s bactericidal activity as indicated by the time-kill assay. While the degree of antibacterial activity may be accounted for by the flavonoids synthesized by plants in response to microbial infection [57], and the active components in the crude extract may be acting synergistically to produce good antibacterial effects [58], the disparity between the activities of the extract and the standard antimicrobial drug may be due to the mixtures of bioactive compounds present in the extract compared to the pure compound contained in the standard antibiotics [54].

Although in vitro tests do not necessarily confirm that plant extracts are either effective medicines or a suitable candidate for drug development, it provides a basic understanding of a plant efficacy and leads to the search for new active substances as well as validating its use in traditional medicine. In ethnomedicine, the recorded antibacterial activity of the crude ethanolic extract of *E. caffra* is of potential importance in the health care delivery system. It showed that the plant could be used as an alternative to orthodox antibiotics in the treatment of infectious diseases caused by these microorganisms. Since investigating the pharmacological activity of plant extract could afford the designing of less expensive therapeutic agents to be used in economically less privileged regions [59], the crude extract could offer a considerable potential opportunity for the development of new agents effective against infections currently difficult to treat [60]. With these expectations, many pharmaceutical companies have renewed their interest in investigating higher plants as sources for new lead structures and the development of standardized antimicrobial agents of proven efficacy, safety, and quality. Consequently, understanding the chemical nature and isolating the active principle(s) in *E. caffra* will provide an opportunity to synthesize new and effective antibacterial drugs.

5. Conclusions

The use of plants in the treatment of infections has been extensively applied by the local populace in South Africa. In this study, the great potential of *E. caffra* in the treatment of microbial infection such as diarrhea was elucidated, while the bactericidal activity of the extract showed that the plant is of medicinal importance. To establish the therapeutic applicability of this plant in the treatment of microbial infections, investigation of its mechanisms of action, in vivo studies, and toxicological effects are ongoing in our research laboratory. A consideration of the degree of the bactericidal activity of the extract showed that there is a need for the isolation of the bioactive compounds. From this study, we concluded that the extract showed broader-spectrum antibacterial activity and can justify the use of *Erythrina caffra* in the folkloric medicine for treating gastrointestinal infections in South Africa.

References

[1] F. C. Tenover, “Mechanisms of antimicrobial resistance in bacteria,” *American Journal of Infection Control*, vol. 34, no. 5, pp. S3–S10, 2006.

[2] M. Simões, L. C. Simões, S. Cleto, I. Machado, M. O. Pereira, and M. J. Vieira, “Antimicrobial mechanisms of ortho-phthalaldehyde action,” *Journal of Basic Microbiology*, vol. 47, no. 3, pp. 230–242, 2007.

[3] B. F. Brehm-Stecher and E. A. Johnson, “Sensitization of *Staphylococcus aureus* and *Escherichia coli* to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone,” *Antimicrobial Agents and Chemotherapy*, vol. 47, no. 10, pp. 3357–3360, 2003.

[4] E. Rossland, T. Langsrud, and T. Sorhaug, “Influence of controlled lactic fermentation on growth and sporulation of *Bacillus cereus* in milk,” *International Journal of Food Microbiology*, vol. 103, no. 1, pp. 69–77, 2005.

[5] Y. Lu, Y. P. Zhao, Z. C. Wang, S. Y. Chen, and C. X. Fu, “Composition and antimicrobial activity of the essential oil of *Actinidia macracarpa* from China,” *Natural Product Research*, vol. 21, no. 3, pp. 227–233, 2007.

[6] K. Lewis and F. M. Ausubel, “Prospects for plant-derived antibacterials,” *Nature Biotechnology*, vol. 24, no. 12, pp. 1504–1507, 2006.

[7] H. O. Edeoga, D. E. Okwu, and B. O. Mbaebie, “Phytochemical constituents of some Nigerian medicinal plants,” *African Journal of Biotechnology*, vol. 4, no. 7, pp. 685–688, 2005.

[8] R. Nawrot, K. Lesniewicz, J. Pienkowski, and A. Gozdziacka-Jozefiak, “A novel extracellular peroxidase and nucleases from a milky sap of *Chelidonium majus*,” *Fitoterapia*, vol. 78, no. 7–8, pp. 496–501, 2007.

[9] A. C. Casburn-Jones and M. J. G. Farthing, “Management of infectious diarrhoea,” *Gut*, vol. 53, no. 2, pp. 296–305, 2004.

[10] A. Prüss, D. Kay, L. Fewtrell, and J. Bartram, “Estimating the burden of disease from water, sanitation, and hygiene at a global level,” *Environmental Health Perspectives*, vol. 110, no. 5, pp. 537–542, 2002.

[11] M. Kosek, C. Bern, and R. L. Guerrant, “The global burden of diarrhoeal disease, as estimated from studies published between 1992–2000,” *Bulletin of the World Health Organization*, vol. 81, no. 3, pp. 197–204, 2003.

[12] S. J. Savarino and A. L. Bourgeois, “Diarrhoeal disease: current concepts and future challenges. Epidemiology of diarrhoeal diseases in developed countries,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 87, supplement 3, pp. 7–11, 1993.

[13] World Health Organization, *Water and Sanitation: Fact Sheet*, vol. 112, World Health Organization, Geneva, Switzerland, 1996.

[14] A. D. Lopez, C. D. Mathers, M. Ezzati, D. T. Jamison, and C. J. L. Murray, “Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data,” *The Lancet*, vol. 367, no. 9524, pp. 1747–1757, 2006.

[15] N. A. Cunliffe, P. E. Kilgore, J. S. Breeze et al., “Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization,” *Bulletin of the World Health Organization*, vol. 76, no. 5, pp. 525–537, 1998.

[16] M. O’Ryan, V. Prado, and L. K. Pickering, “A millennium update on pediatric diarrheal illness in the developing world,”
The Scientific World Journal 7

Seminars in Pediatric Infectious Diseases, vol. 15, no. 2, pp. 125–136, 2005.

[17] M. M. Suleiman, T. Dzenda, and C. A. Sani, “Antidiarrhoeal activity of the methanol stem-bark extract of Annona senegalensis Pers. (Annonaceae),” Journal of Ethnopharmacology, vol. 116, no. 1, pp. 125–130, 2008.

[18] A. L. Otshudi, A. Vercruysse, and A. Foriers, “Contribution to the ethnobotanical, phytochemical and pharmacological studies of traditionally used medicinal plants in the treatment of dysentery and diarrhoea in Lolomela area, Democratic Republic of Congo (DRC),” Journal of Ethnopharmacology, vol. 71, no. 3, pp. 411–423, 2000.

[19] J. Lin, T. Puckree, and T. P. Mvelase, “Anti-diarrhoeal evaluation of some medicinal plants used by Zulu traditional healers,” Journal of Ethnopharmacology, vol. 79, no. 1, pp. 53–56, 2002.

[20] World Health Organization, World Health Report [Internet], Geneva, Switzerland, http://whqlib-doc.who.int/whr/2004/924156265X.pdf, 2004, 120–5.

[21] F. R. Irvine, Woody Plants of Ghana, University Press of London, Oxford, UK, 1961.

[22] H. M. Burkill, The Useful Plants of West Tropical Africa, vol. 3, Families J-L. Royal Botanic Gardens, Kew, Australia, 1995.

[23] M. Roberts, Indigenous Healing Plants, Southern Books, Pretoria, South Africa, 1990.

[24] A. Hutchings, A. H. Scott, G. Lewis, and A. R. Cunningham, Zulu Medicinal Plants: An Inventory, University of Natal Press, Pietermaritzburg, South Africa, 1996.

[25] D. F. Basri and S. H. Fan, “The potential of aqueous and acetone extracts of galls of Quercus infectoria as antibacterial agents,” Indian Journal of Pharmacology, vol. 37, no. 1, pp. 26–29, 2005.

[26] European Committee for Antimicrobial Susceptibility Testing (EUCAST), “Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution,” Clinical Microbiology and Infection, vol. 6, no. 9, pp. 509–515, 2000.

[27] M. C. Cheesbrough, Medical Laboratory Manual for Tropical Countries, vol. 2, ELBS, Tropical Health Technology Publications and Butterworth-Heinemann, Cambridge, UK, 2002.

[28] M. A. Wikler, Performance Standards for Antimicrobial Susceptibility Testing, Seventeenth Informational Supplement, part M2-A9, M100-S17, Clinical and Laboratory Standard Institute, Pennsylvania, Pa, USA, 2007.

[29] M. A. Wikler, Performance Standards for Antimicrobial Susceptibility Testing, Eighteenth informational Supplement, vol. 28, M100-S18, Clinical and Laboratory Standard Institute, Pennsylvania, Pa, USA, 2008.

[30] A. J. Afolayan and J. J. Meyer, “The antimicrobial activity of 3,5,7-trihydroxyflavone isolated from the shoots of Helichrysum aureonitens,” Journal of Ethnopharmacology, vol. 57, no. 3, pp. 177–181, 1997.

[31] C. J. Shanholitzer, L. R. Peterson, and M. L. Mohn, “MBCs for Staphylococcus aureus as determined by macrodilution and microlution techniques,” Antimicrobial Agents and Chemotherapy, vol. 26, no. 2, pp. 214–219, 1984.

[32] D. N. Gerdting, L. R. Peterson, J. A. Moody, and C. E. Fasching, “Melocillin, cefazoxime, and amikacin alone and in combination against six Enterobacteriaceae in a neutropenic site in rabbits,” Journal of Antimicrobial Chemotherapy, vol. 15, supplement A, pp. 207–219, 1985.

[33] D. M. Bamberger, L. R. Peterson, D. N. Gerdting, J. A. Moody, and C. E. Fasching, “Ciprofloxacin, azlocillin, cefazoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model,” Journal of Antimicrobial Chemotherapy, vol. 18, no. 1, pp. 51–63, 1986.

[34] J. A. Moody, C. E. Fasching, L. R. Peterson, and D. N. Gerdting, “Cefazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae,” Diagnostic Microbiology and Infectious Disease, vol. 6, no. 1, pp. 59–67, 1987.

[35] C. E. Fasching, L. R. Peterson, J. A. Moody, L. M. Sinn, and D. N. Gerdting, “Treatment evaluation of experimental staphylococcal infections: comparison of β-lactam, lipopeptide, and glycopeptide antimicrobial therapy,” Journal of Laboratory and Clinical Medicine, vol. 116, no. 5, pp. 697–706, 1990.

[36] R. Irkin and M. Korukluoglu, “Control of Aspergillus niger with garlic, onion and leek extracts,” African Journal of Biotechnology, vol. 6, no. 4, pp. 384–387, 2007.

[37] S. A. Shanmugapriya, A. Manilal, S. Sujith, J. Selvin, G. S. Kiran, and K. Narayanaeensivasan, “Antimicrobial activity of seaweeds extracts against multiresistant pathogens,” Annals of Microbiology, vol. 58, no. 3, pp. 535–541, 2008.

[38] G. M. Etiolopoulos and C. T. Etiolopoulos, “Antibiotic combinations: should they be tested?” Clinical Microbiology Reviews, vol. 1, no. 2, pp. 139–156, 1988.

[39] G. M. Etiolopoulos and R. C. Moellering, “Antimicrobial combinations,” in Antibiotics in Laboratory Medicine, V. Lorain, Ed., pp. 330–396, The Williams & Wilkins, Baltimore, Md, USA, 4th edition, 1996.

[40] R. Cruishank, J. P. Duguid, B. P. Marmion, and R. H. A. Swain, “Medical microbiology,” in The Practice of Medical Microbiology, Churchill Livingstone, London, UK, 12th edition, 1975.

[41] G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum, “Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, ciprofloxacin, ciprofloxacin, and vancomycin by using time-kill methodology,” Antimicrobial Agents and Chemotherapy, vol. 38, no. 9, pp. 2065–2072, 1994.

[42] H. W. Florey, E. Chain, and M. E. Florey, The Antibiotic, vol. 1, Oxford University Press, New York, NY, USA, 1989.

[43] M. H. Scheetz, C. Qi, J. R. Warren et al., “In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumanii,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 5, pp. 1621–1626, 2007.

[44] V. T. Hiremath and T. C. Ranath, “Traditional phyotherapy for snake bites by tribes of Chitradurga District, Karnataka, India,” Ethnobotanical Leaflets, vol. 14, pp. 120–125, 2010.

[45] K. O. Akinyemi, O. Oladapo, C. E. Okwara, C. C. Ibe, and K. A. Fasure, “Screening of crude extracts of six medicinal plants used in South-West Nigerian unorthodox medicine for anti-methicillin resistant Staphylococcus aureus activity,” BMC Complementary and Alternative Medicine, vol. 5, article 6, 2005.

[46] M. Patel and M. M. Coogan, “Antifungal activity of the plant Dodonaea viscosa var. angustifolia on Candida albicans from HIV-infected patients,” Journal of Ethnopharmacology, vol. 118, no. 1, pp. 173–176, 2008.

[47] M. F. Balandrin, J. A. Klocke, E. S. Wurtele, and W. H. Bollinger, “Natural plant chemicals: sources of industrial and medicinal materials,” Science, vol. 228, no. 4704, pp. 1154–1160, 1985.

[48] G. G. F. Nascimento, J. Locatelli, P. C. Freitas, and G. L. Silva, “Antibacterial activity of plant extracts and phytochemicals on antibiotic-resistant bacteria,” Brazilian Journal of Microbiology, vol. 31, no. 4, pp. 247–256, 2000.

[49] F. Guéritte-Voegelie, D. Guénard, F. Lavelle, M. T. Le Goff, L. Mangatal, and P. Potier, “Relationships between the structure
of taxol analogues and their antimitotic activity,” *Journal of Medicinal Chemistry*, vol. 34, no. 3, pp. 992–998, 1991.

[50] J. Srivastava, J. Lambert, and N. Vietmeyer, “Medicinal plants: an expanding role in development,” World Bank Technical Paper 320, 1996.

[51] J. D. McChesney, S. K. Venkataraman, and J. T. Henri, “Plant natural products: back to the future or into extinction?” *Phytochemistry*, vol. 68, no. 14, pp. 2015–2022, 2007.

[52] J. L. Rios and M. C. Recio, “Medicinal plants and antimicrobial activity,” *Journal of Ethnopharmacology*, vol. 100, no. 1-2, pp. 80–84, 2005.

[53] W. Fabry, P. O. Okemo, and R. Ansorg, “Antibacterial activity of East African medicinal plants,” *Journal of Ethnopharmacology*, vol. 60, no. 1, pp. 79–84, 1998.

[54] M. M. Cowan, “Plant products as antimicrobial agents,” *Clinical Microbiology Reviews*, vol. 12, no. 4, pp. 564–582, 1999.

[55] M. Simões, R. N. Bennett, and E. A. Rosa, “Understanding antimicrobial activities of phytochemicals against multidrug resistant bacteria and biofilms,” *Natural Product Reports*, vol. 26, no. 6, pp. 746–757, 2009.

[56] C. A. Mims, J. H. L. Playfair, I. M. Roitt, D. Wakelin, and R. Williams, “Antimicrobials and chemotherapy,” in *Medical Microbiology Review*, C. A. Mims, Ed., vol. 35, pp. 1–34, Mosby Europe, London, UK, 1993.

[57] E. C. Schinor, M. J. Salvador, I. Y. Ito, and D. A. Dias, “Evaluation of the antimicrobial activity of crude extracts and isolated constituents from *Chresta scapigera*,” *Brazilian Journal of Microbiology*, vol. 38, no. 1, pp. 145–149, 2007.

[58] J. N. Eloff, “Which extractant should be used for the screening and isolation of antimicrobial components from plants?” *Journal of Ethnopharmacology*, vol. 60, no. 1, pp. 1–8, 1998.

[59] D. Gatsing, C. F. N. Nkeugouapi, B. F. N. Nkah, J. R. Kuiate, and F. M. Tchouanguet, “Antibacterial activity, bioavailability and acute toxicity evaluation of the leaf extract of *Alchornea cordifolia* (Euphorbiaceae),” *International Journal of Pharmacology*, vol. 6, no. 3, pp. 173–182, 2010.

[60] T. D. B. Machado, I. C. R. Leal, R. M. Kuster et al., “Brazilian phytopharmaceuticals—evaluation against hospital bacteria,” *Phytotherapy Research*, vol. 19, no. 6, pp. 519–525, 2005.